Abstract：
Montelukast by inhibiting leukotriene receptors in the bladder can prevent the activation of mast cells. We investigated the effectiveness of Montelukast in reducing the symptoms of children with bladder pain syndrome (BPS). In this randomized clinical trial, children were allocated into groups of intervention (Montelukast and oxybutynin) and the control (oxybutynin). At the beginning and after 14 days, questions from mothers of children about their urinary condition were asked about the frequency of nocturnal enuresis, frequent urination, urinary incontinence, urinary urgency, and their pain severity. There was no significant difference between two groups in terms of frequency of nocturnal enuresis, frequent urination, urinary incontinence, and urinary urgency. Regarding the frequency of pain distribution, the frequency of pain-free people in the Montelukast group was higher than control group (84.4% vs 56.3%, P = .023). The results showed that adding Montelukast to oxybutynin has a significant decrease in pain in children with BPS.
摘要：
孟鲁司特通过抑制膀胱中的白三烯受体可以防止肥大细胞的活化。我们调查了孟鲁司特在减轻膀胱疼痛综合征（BPS）儿童症状方面的有效性。在这项随机临床试验中，将儿童分为干预组(孟鲁司特和奥昔布宁)和对照组(奥昔布宁).在开始和14天后，孩子的母亲关于他们的泌尿情况的问题被问及夜间遗尿症的频率，尿频,尿失禁,尿急,以及疼痛的严重程度。两组患者夜间遗尿症的发生频率无显著差异,尿频,尿失禁,和尿急。关于疼痛分布的频率，孟鲁司特组无痛人群频率高于对照组(84.4%vs56.3%,P=.023）。结果表明，在奥昔布宁的基础上添加孟鲁司特对BPS患儿的疼痛有明显的减轻作用。
